NAD+ and Lupus: Why There's a Real Trial, But No Results Yet

Written by the Nuvirox Research Team

Short answer: there's a legitimate, government-funded human trial underway, which is more than exists for many NAD+ topics — but it hasn't reported results, so there's nothing yet to confirm or deny an actual benefit. If you or someone you know has lupus and came across this connection, it's worth understanding exactly where the science stands: a real question being asked in a real trial, with the answer still pending.

A note before going further

Systemic lupus erythematosus (SLE) is a serious, chronic autoimmune disease that can affect the skin, joints, kidneys, and other organs, with disease severity varying widely between individuals. This article discusses ongoing research into a specific immune mechanism — it is not treatment guidance, and lupus should always be managed under the care of a rheumatologist. Nothing here should be read as a substitute for that relationship or for prescribed treatment.

Why NAD+ research has turned toward lupus

Lupus involves overactivation of the immune system, particularly a signaling pathway called type I interferon activation, along with dysfunction in certain white blood cells (neutrophils). Research has found that neutrophils in women — who make up the large majority of lupus patients — tend to have reduced mitochondrial energy capacity, which affects how their immune cells behave metabolically. Because NAD+ availability is directly tied to mitochondrial function, and separate research has shown that boosting NAD+ with nicotinamide riboside can reduce type I interferon activation in blood cells from healthy volunteers, researchers had a specific, mechanistic reason to test whether the same effect might help calm the overactive immune signaling seen in lupus.

What the trial is actually testing

A double-blind, placebo-controlled trial (NCT06032923), sponsored by the National Heart, Lung, and Blood Institute (part of the NIH), is currently recruiting female SLE patients to test nicotinamide riboside's effects on immune cell metabolism and inflammatory signaling. The trial's primary endpoint is whether NR supplementation reduces type I interferon signaling (measured via a specific marker, interferon-beta secretion from monocytes) compared to placebo. Exploratory endpoints include detailed metabolic profiling of immune cells and, because type I interferon activation is also linked to blood vessel dysfunction and cardiovascular risk in lupus, an assessment of NR's effect on endothelial function.

Why "there's a trial" is not the same as "it works"

It's worth being explicit here, because a recruiting NIH trial can sound like validation on its own. It isn't — it means the underlying hypothesis was judged strong enough by NIH reviewers to fund a rigorous test, which is a meaningful scientific milestone, but it says nothing yet about the outcome. Trials fail to show benefit more often than popular science coverage implies, including trials built on strong preclinical rationale (the diabetic neuropathy trial discussed elsewhere on this site is a direct example of exactly that happening with an NAD+ precursor). Until this lupus trial reports results, the honest status is "an important open question," not "a promising treatment."

What actually has strong evidence for lupus

Lupus management has real, extensively studied treatment options: hydroxychloroquine is a cornerstone medication for most SLE patients with strong trial evidence, corticosteroids and various immunosuppressants are used depending on disease severity and organ involvement, and newer biologic medications (like belimumab and anifrolumab, which specifically targets the type I interferon pathway discussed above) have randomized trial support for more severe or refractory disease. Sun protection, careful monitoring for organ involvement (especially kidney function), and cardiovascular risk management are also core, evidence-based parts of lupus care.

What NAD+ won't do for lupus right now

Based on current evidence, an NAD+ precursor should not be used as a substitute for prescribed lupus treatment, and no claims should be made about it managing or improving lupus until the ongoing trial reports results. Lupus flares, new symptoms, or signs of organ involvement (like swelling, blood in urine, or significant fatigue changes) need prompt attention from a rheumatologist.

Why the interferon pathway specifically matters here

It's worth explaining why researchers focused on type I interferon signaling rather than lupus symptoms more broadly. This pathway is considered central enough to lupus biology that an entire class of biologic medication, anifrolumab, was developed specifically to block it, and gained regulatory approval based on trial evidence showing it reduced disease activity. The NR lupus trial is testing whether a much simpler, oral supplement can nudge the same pathway in a beneficial direction, using interferon-beta secretion as a direct, measurable readout rather than relying only on symptom questionnaires. That's a scientifically disciplined way to test the hypothesis — but it also means a positive result on this specific lab marker wouldn't automatically prove a benefit for lupus symptoms or long-term outcomes; that would likely require a larger follow-up study.

Frequently asked questions

Is the lupus trial testing NAD+ as a replacement for standard lupus medication?

No — trial participants would be expected to continue their standard lupus care; this trial is studying NR as a potential add-on affecting a specific immune pathway, not as a replacement for hydroxychloroquine or other prescribed treatments.

When will results from this trial be available?

There's no published timeline available as of this writing, since the trial is still recruiting. Results, once published, would typically appear on ClinicalTrials.gov and in a peer-reviewed journal.

Should someone with lupus try an NAD+ supplement while waiting for results?

This is a decision to make with a rheumatologist, who can weigh it against your specific treatment plan and any medication interactions. It shouldn't be treated as a proven or evidence-based lupus intervention at this stage.

Why does lupus affect mostly women?

The reasons are an active area of research involving hormonal, genetic, and X-chromosome-related immune factors; roughly nine out of ten people diagnosed with lupus are women, which is part of why this particular trial is enrolling female patients specifically.

The bottom line

NAD+ and lupus is a genuinely open scientific question being tested in a real, NIH-funded, placebo-controlled trial — which puts it in a different category from purely anecdotal or preclinical-only topics. But an open question with a trial underway is still an open question, not an answer, and lupus management should stay firmly with a rheumatologist using established treatments while this research plays out. Related reading: NAD+ and the immune system and NAD+ and inflammation.

References

1. Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus. ClinicalTrials.gov Identifier: NCT06032923. Sponsor: NHLBI/NIH. Status: recruiting.
2. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. PMID: 32873589.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.